Listen to article
6:26Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 23 September 2026
Read article
Published on 23 September 2026
Read article
Published on 23 September 2026
Read article
Published on 22 September 2026
Read article
Published on 22 September 2026
Read article
Let’s be honest, none of us are getting any younger. I think the moment you start making a noise when you stand up is the moment you realise that the human body is a magnificent, yet flawed, piece of engineering with a decidedly finite warranty. And whilst that’s a rather grim thought for a Tuesday morning, it’s also the bedrock of one of the most compelling investment stories of our time. I’m talking about medical technology, or MedTech, the sector that’s quietly turning the art of medicine into a precise, data-driven science.
This isn't about finding the next miracle pill. To me, that’s a lottery. This is about the tools, the machines, and the systems that are fundamentally changing how healthcare is delivered. It’s about the unstoppable, predictable march of demographics meeting the relentless pace of innovation.
For years, the image of surgery has been one of steady hands and sharp scalpels. That’s changing, and fast. The new operating theatre is home to multi-armed robots performing intricate procedures with a precision that a human surgeon, no matter how gifted, simply cannot match. It sounds like science fiction, but it’s happening in hospitals all over the world, right now.
From an investor’s point of view, the real beauty isn’t just the incredible technology. It’s the business model. It’s the classic razor and blades strategy, but for saving lives. A hospital buys a multi-million-pound surgical system, and suddenly they are locked into a long-term relationship. They need specialised instruments for every single operation, ongoing maintenance, and constant software updates. It’s a beautiful stream of recurring, high-margin revenue that is the envy of almost any other industry.
You can debate the future of electric cars or the metaverse until you’re blue in the face, but some trends are simply not up for discussion. The world is getting older. Fact. By 2050, the number of people over 60 is set to double. This isn’t a forecast, it’s a demographic certainty. An older population requires more medical care, more joint replacements, more cardiac monitoring, and more diagnostic tests.
This creates a powerful, sustained tailwind for the companies providing these services. It’s a demand curve that is almost entirely insulated from the whims of the economic cycle. People stop buying new cars in a recession, they don’t stop needing a new hip. At the same time, rising wealth in emerging economies is opening up vast new markets, creating a global appetite for the very best in medical care.
In this arena, a few giants cast very long shadows. You have companies like Johnson & Johnson, a sprawling empire whose reach extends from orthopaedics to surgical robotics. Then there’s Abbott Laboratories, which has become a master of managing chronic diseases like diabetes with its clever monitoring devices. And of course, Medtronic, one of the original pioneers that remains a leader in everything from cardiac care to neurosurgery.
These aren't plucky startups, they are the established generals of the healthcare battlefield. It’s no surprise that these are the very titans you’d expect to see anchoring a portfolio like the Healthcare Innovation: MedTech Giants Portfolio 2025, which focuses on exactly this kind of market dominance. They have the scale, the research budgets, and the global networks to not just innovate, but to commercialise that innovation effectively.
View the full Basket:Healthcare Innovation: MedTech Giants Portfolio 2025
View the full Basket:Healthcare Innovation: MedTech Giants Portfolio 2025
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 23 September 2026
Read article
Published on 23 September 2026
Read article
Published on 23 September 2026
Read article
Published on 22 September 2026
Read article
Published on 22 September 2026
Read article
